Plaque Psoriasis in 68 Market is Expected to Reach USD 26.9 Billion by 2034

Plaque psoriasis, the most common form of psoriasis, is a chronic autoimmune skin disorder characterized by red, scaly plaques resulting from overactive immune signaling that accelerates skin cell turnover. Affecting over 125 million people globally, the disease not only causes visible discomfort but also leads to substantial psychosocial and economic burdens.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73643

Recent years have witnessed an unprecedented evolution in psoriasis treatment. The market has moved beyond traditional topical and phototherapy treatments toward advanced biologics and small molecule inhibitors, offering long-term disease control and improved quality of life. Fueled by the growing adoption of interleukin-targeted therapies, biosimilars, and digital dermatology platforms, the plaque psoriasis market is entering a high-growth phase that will redefine chronic skin disease management through 2034.

Market Overview
• Market Size (2024): USD 11.3 billion (estimated)
• Forecast (2034): USD 26.9 billion
• CAGR (2024-2034): ~8.9%

Key Growth Drivers:
• Rising global prevalence of psoriasis, especially plaque-type cases.
• Increasing use of biologics (IL-17, IL-23, and TNF inhibitors).
• Technological innovations in patient management and teledermatology.
• Expanding access to biosimilars, making advanced therapy more affordable.

Challenges:
• High cost of biologic and small-molecule treatments.
• Unequal access to dermatologic care in developing nations.
• Long-term disease management and recurrence issues.

Leading Companies:
AbbVie Inc., Novartis AG, Eli Lilly and Company, Amgen Inc., Johnson & Johnson, Bristol Myers Squibb, UCB Pharma, Pfizer Inc., Leo Pharma A/S, Sun Pharmaceutical Industries Ltd.

Segmentation Analysis
By Treatment Type
• Biologics (IL-17 Inhibitors, IL-23 Inhibitors, IL-12/23 Inhibitors, TNF Inhibitors)
• Small Molecule Therapies (PDE4 Inhibitors, JAK Inhibitors)
• Topical Agents (Corticosteroids, Vitamin D Analogs, Calcineurin Inhibitors)
• Phototherapy
• Others (Combination Therapies, Emerging Modalities)

By Route of Administration
• Injectable
• Oral
• Topical

By Severity Level
• Mild
• Moderate
• Severe

By End User
• Hospitals & Dermatology Clinics
• Specialty Pharmacies
• Homecare Settings
• Research & Academic Institutes

Summary:
Biologics dominate the global market, accounting for the highest revenue share due to superior efficacy and long-term disease control. IL-17 and IL-23 inhibitors are the fastest-growing classes, offering targeted treatment with improved safety. Meanwhile, small molecule drugs like PDE4 and JAK inhibitors are emerging as convenient oral options. Topical agents continue to play an essential role for mild to moderate cases.

Explore Full Report here: https://exactitudeconsultancy.com/reports/73643/plaque-psoriasis-in-68-market

Regional Analysis
North America
• Largest market in 2024 due to widespread availability of biologics, strong insurance coverage, and rapid adoption of new therapies.
• The U.S. leads with approvals of Skyrizi (AbbVie), Cosentyx (Novartis), and Taltz (Eli Lilly).
Europe
• Strong clinical adoption in Germany, France, and the UK supported by national healthcare systems.
• EMA approvals driving biosimilar competition and cost-effective access.
Asia-Pacific
• Fastest-growing region (CAGR ~10.4%) due to increasing prevalence, growing awareness, and local biosimilar production.
• China, India, and Japan emerging as key growth markets.
Middle East & Africa
• Growing market share in GCC nations with expanding dermatology clinics and higher disposable incomes.
• Limited access in rural regions and underdeveloped healthcare systems.
Latin America
• Moderate growth driven by expanding dermatological infrastructure and public health initiatives in Brazil and Mexico.

Summary:
While North America and Europe currently dominate the market, Asia-Pacific is poised to become the fastest-growing region, driven by biosimilar expansion, improved diagnosis, and government-led healthcare reforms.

Market Dynamics
Key Growth Drivers
• Expansion of biologic pipelines with next-generation IL inhibitors.
• Increasing demand for personalized and precision dermatology.
• Rising use of digital platforms for remote monitoring and teleconsultation.
• Growing patient awareness and social acceptance of chronic skin conditions.

Key Challenges
• Cost-related barriers and reimbursement limitations for biologic therapies.
• Long-term adherence challenges and disease recurrence.
• Limited dermatologist availability in emerging economies.

Latest Trends
• Surge in biosimilar approvals improving treatment affordability.
• Integration of AI in dermatology diagnostics and treatment monitoring.
• Development of oral small molecules (deucravacitinib, apremilast) for easier administration.
• Focus on patient-centered care with mobile apps and wearable adherence tracking.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73643

Competitor Analysis
Major Players:
• AbbVie Inc.
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Johnson & Johnson
• Bristol Myers Squibb
• UCB Pharma
• Pfizer Inc.
• Leo Pharma A/S
• Sun Pharmaceutical Industries Ltd.

Competitive Landscape:
The plaque psoriasis market is highly competitive and innovation-driven. AbbVie's Skyrizi (IL-23 inhibitor) and Eli Lilly's Taltz (IL-17A inhibitor) lead the field in market adoption and patient outcomes. Novartis' Cosentyx remains a blockbuster biologic, while Pfizer and Bristol Myers Squibb are investing in oral therapies such as deucravacitinib, targeting moderate cases. The introduction of biosimilars and next-generation IL-17F inhibitors is intensifying competition and improving affordability across regions.

Conclusion
The Plaque Psoriasis Market (In-68) is projected to grow from USD 11.3 billion in 2024 to USD 26.9 billion by 2034, at a CAGR of 8.9%. Fueled by breakthroughs in biologics, the emergence of small molecule inhibitors, and increasing accessibility of biosimilars, the market outlook remains robust and transformative.

Despite high treatment costs and adherence challenges, innovations in AI-assisted dermatology, digital adherence monitoring, and personalized immunotherapy are reshaping care standards. Asia-Pacific's growing influence and biosimilar production capabilities are further expanding global reach.

Key Takeaway: Companies that integrate next-generation IL-targeted biologics, digital patient engagement tools, and precision dermatology platforms will lead the next decade of plaque psoriasis care, bridging efficacy with affordability.

This report is also available in the following languages : Japanese (68人の尋常性乾癬), Korean (68세의 플라크 건선), Chinese (68 例斑块状银屑病), French (Psoriasis en plaques chez 68), German (Plaque-Psoriasis bei 68), and Italian (Psoriasi a placche nel 68), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/73643/plaque-psoriasis-in-68-market#request-a-sample

Our More Reports:

Digital Thermo Anemometer Market
https://exactitudeconsultancy.com/reports/75213/digital-thermo-anemometer-market

Multi-Screen Super Glass Market
https://exactitudeconsultancy.com/reports/75214/multi-screen-super-glass-market

Mining Pneumatic Saw Market
https://exactitudeconsultancy.com/reports/75215/mining-pneumatic-saw-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.